[Excerpt] Takeda is defending its key brands on multiple fronts this year, but it’s the loss of exclusivity on Vyvanse—the Japanese pharma’s third best-selling product—that’s going to hurt the most. First approved back in 2007 to treat attention-deficit/hyperactivity disorder (ADHD), Vyvanse—known generically as lisdexamfetamine dimesylate—will likely face its first copycat competitors after the drug’s last U.S. patent runs its course in August.